Agenda-Schedule-Fall-2019-1

Thank you for supporting the 2019 FLASCO Fall Session!

 EXHIBIT INFO:  We are expecting 150-175 attendees at the FLASCO Fall Session.  Click here to view the 2019 Fall Session Attendee Roster.

EXHIBITORS

21st Century

AbbVie Pharmaceuticals

Acrotech Biopharma

Adaptive biotechnologies

Advanced Accelerator Applications, a Novartis company

Agios Pharmaceuticals

Alexion Pharmaceuticals

AMAG Pharmaceuticals

Amgen Oncology

Array Biopharma

Astellas Pharma

AstraZeneca

Bayer Healthcare

BeiGene

Boehringer Ingelheim

Briova Rx

Bristol-Myers Squibb

Caris Life Sciences

Celgene

Cleveland Clinic

Clovis Oncology

Coherus Biosciences

Daiichi Sankyo

Dova Pharmaceuticals

East Central Florida Cancer Control Collaborative

Eisai

EMD Serono

Equashield

EUSA Pharma

Exelixis

Florida Cancer Data System

Foundation Medicine

Genentech

Genomic Health

Gilead Sciences

Guardant Health

Helsinn Therapeutics

IBM Watson Healthcare

Immunomedics

Incyte

Ipsen Biopharmaceuticals

Johnson & Johnson

Kite Pharma

Kroger Specialty Pharmacy

Lilly Oncology

McKesson Specialty Health

Merck

Moffitt Cancer Center

NanoString Technologies

Natera

New Century Health

Novartis

Oncology Supply/ION Solutions

Pfizer Oncology

Pharmacyclics

Puma Biotechnology

Rigel Pharmaceuticals

Roche Diagnostics

Rx Vantage

Sanofi Genzyme

Seattle Genetics

Stemline

Sun Pharma

Surterra Wellness

Taiho Oncology

Takeda Oncology

Tempus

TESARO

Teva Pharmaceuticals

The Leukemia and Lymphoma Society

UF Health Cancer Center

Walgreens Specialty Pharmacy

 

Accreditation and Credit Statements

 

Evaluation & Certificate of Attendance

• A link to the evaluation survey will be emailed to you post-program. Please complete this within the allotted time frame. If you do not receive a post-program email by 11/15/19, reach out to the FLASCO office.
• Your certificate of attendance will be emailed to you for download immediately after submission. Keep the certificate of attendance document for your files.

 

In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician: This activity has been approved for AMA PRA Category 1 Credit(s)^TM.

Nurse/Advanced Nurse Practitioner: This activity has been approved for ANCC contact hours.

Pharmacist: This Application-based activity has been approved for ACPE contact hours.

Physician Assistant: NCCPA accepts AMA PRA Category 1 Credit(s)^TM from organizations accredited by ACCME or a recognized state medical society.

Disclosure Policy – The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content.  MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners.  The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.  CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession. 

Disclosure of Unlabeled Use – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

Disclaimer – Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Abstracts for Poster Presentation

FLASCO Members Accepted Poster Abstracts

Ollie Anum, B.S., PharmD   

Review on CTL019 and KTEC19, CART-cell Agents used for the Treatment of Large B-cell Lymphoma                

Dharti Patel, Oak Hill Hospital

Mariya Fatakhova,Larkin University-College of Pharmacy

Mio Ezura, Nova Southeastern University

Nirali Vassa, Oak Hill Hospital

Ricardo Parrondo, MD, Mayo Clinic Florida

 

Accepted Industry Poster Abstracts 

Rama Blaraman, MD, Florida Cancer Affiliates, Bristol-Myers Squibb

Heather Copher-Sweeney, PharmD, Bristol-Myers Squibb

Trevor McKibbin, PharmD, Pfizer Oncology

Jennifer Sibley, Bristol-Myers Squibb

Jeff Steinberg, PharmD, Pfizer Oncology

Jessica Unzaga, PharmD, BCPS, Baptist Health South, Pfizer Oncology

Josean Vargas-Maisonet, PharmD

Nichole Allen & Yingtao Zhang, MD, Merck

 

 

Renaissance Orlando at SeaWorld 

6677 Sea Harbor Drive, Orlando, Florida

1-407-351-5555

1-800-266-9432

 

General Session	Innovative Solutions and Best Practices in Clinical Research	Howard “Skip” Burris III, MD, FACP, FASCO
General Session	Breast Cancer Management: Emphasis on Immunotherapy	Hope S. Rugo, MD
Multidisciplinary	Multiple Myeloma and AL Amyloidosis Case Study	Raymond Comenzo, MD Emily Jonczak, MD
Pharmacy	USP 800: Beyond the Basics Part II Stronger Together	Lilit Smith, PharmD, MBA Marie Anne Louis-Jeune, PharmD, BCPS
Pharmacy	Updates in Immunotherapy & Rare Immunotherapy Toxicity Management: A case based approach	Jennifer Swank, PharmD
APP/Nurse/Navigator	Oncologic Emergencies	Lisa Welsh, MBA, PA-C
APP/Nurse/Navigator	Sexual Health in Oncology	Maray Salina, MSN, RN, NP-C
Administrator	Telemedicine	Bill Manzie, MBA
Lunch Presentation	The Benefits of Prescreening for Lung Cancer	Luis E. Raez, MD, FACP, FOCP
Lunch Presentation	Role of R2 in Previously Treated Follicular Lymphoma	Celeste Bello, MD, MSPH
Lunch Presentation	Using Huddles to Empower, Change, and Improve Employee Communication and Enhance Patient Care	Carie Colby
Multidisciplinary	Colon Cancer: A discussion regarding diagnosis and treatment for a patient under 50	Mintallah Haider, MD with Panel of Experts
Pharmacy	Biosimilars: Beyond the Scientific Review	Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Pharmacy	Updates in Gastrointestinal Cancers	Anand Shah, Pharmd, BCOP, BCPS
Pharmacy	Navigating Your Way to Medication Assistance Program Success	Susan Downey, PharmD c/o Angelica Berni, PharmD
APP/Nurse/Navigator	USP 800: Beyond the Basics	Lilit Smith, PharmD, MBA
APP/Nurse/Navigator	Artificial Intelligence	Mehool Patel, MD, MBA, FACP
APP/Nurse/Navigator	Survivorship Care Planning: Best Practices	Rick McDonough, MD Smitha Pabbathi, MD Karen Stephenson, DNP, MBA, APRN, OCN
Administrator	Challenges with Specialized Testing	Rise Marie Cleland
Administrator	Prior Authorization Burdens	Rise Marie Cleland Andrew Hertler, MD, FACP